| REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, ... New England Journal of Medicine 384 (3), 238-251, 2021 | 1870 | 2021 |
| Combined oral contraceptives in women with systemic lupus erythematosus M Petri, MY Kim, KC Kalunian, J Grossman, BH Hahn, LR Sammaritano, ... New England Journal of Medicine 353 (24), 2550-2558, 2005 | 1303 | 2005 |
| REGEN-COV antibody combination and outcomes in outpatients with Covid-19 DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, J Xiao, ... New England Journal of Medicine 385 (23), e81, 2021 | 680 | 2021 |
| Subcutaneous REGEN-COV antibody combination to prevent Covid-19 MP O’Brien, E Forleo-Neto, BJ Musser, F Isa, KC Chan, N Sarkar, KJ Bar, ... New England Journal of Medicine 385 (13), 1184-1195, 2021 | 506 | 2021 |
| Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, ... JAMA dermatology 156 (1), 44-56, 2020 | 502 | 2020 |
| Conjunctivitis in dupilumab clinical trials B Akinlade, E Guttman‐Yassky, M de Bruin‐Weller, EL Simpson, ... British Journal of Dermatology 181 (3), 459-473, 2019 | 436 | 2019 |
| Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo … AS Paller, EC Siegfried, D Thaçi, A Wollenberg, MJ Cork, PD Arkwright, ... Journal of the American Academy of Dermatology 83 (5), 1282-1293, 2020 | 384 | 2020 |
| Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study M Deleuran, D Thaçi, LA Beck, M de Bruin-Weller, A Blauvelt, S Forman, ... Journal of the American Academy of Dermatology 82 (2), 377-388, 2020 | 268 | 2020 |
| Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial M Worm, EL Simpson, D Thaçi, R Bissonnette, JP Lacour, S Beissert, ... JAMA dermatology 156 (2), 131-143, 2020 | 188 | 2020 |
| Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension MJ Cork, D Thaçi, LF Eichenfield, PD Arkwright, T Hultsch, JD Davis, ... British Journal of Dermatology 182 (1), 85-96, 2020 | 160 | 2020 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 118 | 2022 |
| A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to< 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy AS Paller, EC Siegfried, EL Simpson, MJ Cork, B Lockshin, MP Kosloski, ... Journal of the European Academy of Dermatology and Venereology 35 (2), 464-475, 2021 | 87 | 2021 |
| In vivo–in vitro correlation (IVIVC) modeling incorporating a convolution step T O'hara, S Hayes, J Davis, J Devane, T Smart, A Dunne Journal of pharmacokinetics and pharmacodynamics 28, 277-298, 2001 | 83 | 2001 |
| Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations M Gertz, JD Davis, A Harrison, JB Houston, A Galetin Current drug metabolism 9 (8), 785-795, 2008 | 81 | 2008 |
| Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development J Wang, S Iyer, PJ Fielder, JD Davis, R Deng Biopharmaceutics & drug disposition 37 (2), 51-65, 2016 | 73 | 2016 |
| Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based … G Allan, J Davis, M Dickins, I Gardner, T Jenkins, H Jones, R Webster, ... Xenobiotica 38 (6), 620-640, 2008 | 69 | 2008 |
| Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL‐4Rα, in atopic dermatitis patients and normal volunteers P Kovalenko, AT DiCioccio, JD Davis, M Li, M Ardeleanu, NMH Graham, ... CPT: Pharmacometrics & Systems Pharmacology 5 (11), 617-624, 2016 | 62 | 2016 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects Z Li, A Radin, M Li, JD Hamilton, M Kajiwara, JD Davis, Y Takahashi, ... Clinical pharmacology in drug development 9 (6), 742-755, 2020 | 60 | 2020 |
| Evaluation of potential disease‐mediated drug–drug interaction in patients with moderate‐to‐severe atopic dermatitis receiving dupilumab JD Davis, A Bansal, D Hassman, B Akinlade, M Li, Z Li, B Swanson, ... Clinical Pharmacology & Therapeutics 104 (6), 1146-1154, 2018 | 56 | 2018 |
| Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart … A Baruch, S Mosesova, JD Davis, N Budha, A Vilimovskij, R Kahn, K Peng, ... The American journal of cardiology 119 (10), 1576-1583, 2017 | 56 | 2017 |
Diamant ThaciProfessorכתובת אימייל מאומתת בדומיין uksh.de